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Acute megakaryocytic leukemia (AMKL) with t(1 ; 22)(p13 ; q13) is a distinct category of myeloid leu-
kemia by WHO classiﬁcation and mainly reported in infants and young children.  Accurate diagnosis 
of this type of AMKL can be diﬃcult,  because a subset of patients have a bone marrow (BM) blast 
percentage of less than 20ｵ due to BM ﬁbrosis.  Therefore,  it is possible that past studies have under-
estimated this type of AMKL.  We present here the case of a 4-month-old female AMKL patient who 
was diagnosed by presence of the RBM15-MKL1 (OTT-MAL) fusion transcript by RT-PCR.  In addi-
tion,  we monitored RBM15-MKL1 fusion at several time points as a marker of minimal residual dis-
ease (MRD),  and found that it was continuously negative after the ﬁrst induction chemotherapy even 
by nested RT-PCR.  Detection of the RBM15-MKL1 fusion transcript thus seems to be useful for 
accurate diagnosis of AMKL with t(1 ; 22)(p13 ; q13).  We recommend that the RBM15-MKL1 fusion 
transcript be analyzed for all suspected AMKL in infants and young children.  Furthermore,  monitor-
ing of MRD using this fusion transcript would be useful in treatment of AMKL with t(1 ; 22)(p13 ; q13).
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nfant acute megakaryoblastic leukemia (AMKL) 
with t(1 ; 22)(p13 ; q13) is a distinctive myeloid 
malignancy by WHO classiﬁcation,  representing ＜1ｵ 
of all acute myeloid leukemia (AML) cases [1].  The 
prognosis of all AMKL is usually worse than that of 
other AML types,  except for Down syndrome (DS)-
related AMKL with GATA1 mutation,  but AMKL 
with t(1 ; 22)(p13 ; q13) appears to be uncertain.  
Some studies have found that AMKL patients with 
t(1 ; 22)(p13 ; q13) respond well to intensive AML 
chemotherapy and achieve long disease-free survival 
[1,  2].  Furthermore,  the disease is mainly reported 
in infants and young children,  and most cases occur in 
the ﬁrst 6 months of life (median,  4 months) [1].  
However,  the diagnosis of AMKL can be diﬃcult,  
because a subset of patients have a bone marrow (BM) 
blast percentage of less than 20ｵ due to diﬃculties 
with BM aspiration secondary to ﬁbrosis.
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　 On the other hand,  this translocation also gener-
ates the fusion of the RNA-binding motif protein-15 
(RBM15) (also known as OTT) and megakaryocyte 
leukemia-1 (MKL1) (also known as MAL) genes [3].  
The resulting fusion gene modulates HOX-induced 
diﬀerentiation and extracellular signaling pathways 
[4].
　 In addition,  the detection of minimal residual dis-
ease (MRD) is important for leukemia treatment,  and 
is generally achieved using either ﬂowcytometry [5] 
or detection of the RBM15-MKL1 fusion transcript by 
reverse transcription polymerase chain reaction (RT- 
PCR) [6].
　 We present here the case of a 4-month-old female 
with a low blast count in BM aspirate because of 
ﬁbrosis.  RBM15-MKL1 fusion was only detected by 
RT-PCR in the ﬁrst diagnostic BM sample,  it was not 
detected after the ﬁrst induction chemotherapy even 
by the nested RT-PCR method.  Further,  the fusion 
transcript was not detected at about 2 years after the 
ﬁrst induction chemotherapy.  We will discuss the 
clinical outcome of this rare case of infant AMKL and 
the usefulness of this fusion gene as a marker of MRD.
Materials and Methods
　 Total RNA was extracted from BM mononucleated 
cells at the ﬁrst diagnosis,  after the ﬁrst induction 
chemotherapy,  after the second chemotherapy,  at the 
end of chemotherapy and at 12 months after the end of 
chemotherapy.  RNAs were reverse-transcribed to 
cDNA with a cDNA Synthesis Kit (Amersham 
Bioscience,  Tokyo,  Japan).  Polymerase chain reac-
tion (PCR) was performed using the primer pair of 
RBM15-S1,  which was located in RBM15 exon 1 
(GenBank accession no.  NM_022768.4),  and MKL-AS2,  
which was located in MKL1 exon 5 (GenBank acces-
sion no.  NM_020831.3) as described previously [7].  
We ampliﬁed a control gene (B2M) to check the mRNA 
integrity [7].  The PCR product was directly sequenced 
using an ABI 310 sequencer (Applied Biosystems,  
Tokyo,  Japan).  As a further analysis,  we also per-
formed a nested RT-PCR using the inner primer pair 
of OTT-MAL inner F (5ʼ-cttcatgccttcccacctt-3ʼ) and 
OTT-MAL inner R (5ʼ-tccaagctccttctctgctc-3ʼ).
　 Patient. A 4-month-old female baby was admit-
ted to the hospital because of insuﬃcient gain of body 
weight and poor sucking with hepatosplenomegaly.  
She was delivered at 39 weeks gestation,  and her 
birth weight and height were 3,026g and 47.0cm.  
There were no complications at birth and no typical 
family history.  Laboratory data showed anemia and 
thrombocytopenia with a low blast count (Table 1).  A 
total of 4 BM aspirations were performed because of 
“dry tap” aspirate.  BM biopsy revealed severe BM 
ﬁbrosis with small round blasts resembling lympho-
blasts (Fig.  1A,  1B).  There was no evidence of 
cytomegalovirus infection.  The tentative diagnosis was 
infant AML (FAB classiﬁcation,  M7).  She received a 
ﬁrst induction chemotherapy based on the Japanese 
AML05 protocol (VP16,  cytarabine,  and antracy-
cline) with a 2/3 reduced dose and achieved a complete 
remission (CR).  After the CR,  she received an addi-
tional 4 courses of chemotherapy and was discharged 
from the hospital.  She was healthy at 1.5 year after 
the end of chemotherapy.
Results
　 RBM15-MKL1 fusion was detected in only the ﬁrst 
diagnostic sample by RT-PCR (Fig.  2A).  The fusion 
of exon 1 of RBMK15 to exon 5 of NKL1 was con-
ﬁrmed by direct sequencing (Fig.  2B).  This fusion 
gene was not completely detected after the ﬁrst induc-
tion chemotherapy,  even by a nested RT-PCR at 18 
months after the end of chemotherapy.
Discussion
　 AMKL with t(1 ; 22)(p13 ; q13) is rarely reported,  
represented ＜1ｵ of all AML but occurred with 
120 Acta Med.  Okayama　Vol.  68,  No.  2Takeda et al.
Table 1　 Laboratory data at admission to the hospital
WBC (×106/ml) 8,200 T.Bil (mg/dl) 0.6
　Myelo (%) 1 AST (IU/L) 31
　St (%) 3 ALT (IU/L) 15
　Seg (%) 6 LDH (IU/L) 519
　Eos (%) 2 BUN (mg/dl) 6.4
　Bas (%) 1 Cr (mg/dl) 0.21
　Mon (%) 3 CRP (mg/dl) 0.05
　Lymph (%) 75
　Blast (%) 9
RBC (×109/ml) 164 BM aspiration
Hb (g/dl) 4.5 NCC (×106/ml) 38
Hct (%) 14.2 Mgk (×103/ml) 15
Plt (×106/ml) 9 Blast (%) 7.2
Ret (%) 2.2
higher incidence in the pediatric population and 
accounts for about 70ｵ of AMKL in infants [2].  
However,  in the AML99 study performed in Japan 
from 2000-2002,  only 3 patients were diagnosed as 
having AMKL with t(1 ; 22)(p13 ; q13) among 11 non-
Down AMKL patients.  Accurate diagnosis appeared 
to be diﬃcult because of the diﬃculty of accurately 
detecting this karyotypic abnormality.  Ballerini et al.  
also reported that the real frequency of OTT-MAL 
(RBM15-MKL1) recombination events may be underes-
timated at least in children with AMKL [13].  
Therefore,  we strongly recommend that an RT-PCR 
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Fig. 1　 Images of blasts in the peripheral blood (A) and bone marrow (B) at the ﬁrst diagnosis.  The blasts are round and resemble lym-
phoblasts.
180bp→
β2 microgloblin AS2 (RBM15-S1＋MKL-AS2)
M 1  2 3 5 M 1 2 3 4 54
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A B
Fig. 2　 RBM15 -MKL1  fusion transcript detected by RT-PCR.  A,  The RBM15 -MKL1  fusion transcript was detected only in the ﬁrst 
diagnostic sample by RT-PCR.  Lane M: molecular marker (100bp); lanes 1-5: samples at the diagnosis (1),  after 1 course of induction 
chemotherapy (2),  after 2 courses of chemotherapy (3),  at the end of chemotherapy (4),  and a negative control (5) (the right side of each 
panel shows the result for PCR product of β2 microglobulin and the left side shows the result for the AS2 product).  The fusion product at 
the diagnostic sample was completely negative after starting chemotherapy and even by the nested RT-PCR method (data not shown); B,  
Results of the direct sequencing of the fusion product from the diagnostic sample.  The fusing of exon 1 of RBMK15  to exon 5 of NKL1  was 
conﬁrmed by direct sequencing.
assay for the RBM15-MKL1 fusion transcript be per-
formed for all infants and young children with AMKL.  
However,  the unavailability of BM mononucleated 
cells remains a problem due to BM ﬁbrosis in AMKL.  
Therefore,  if we could perform this analysis using 
RNA extracted from paraﬃn-embedded specimens,  
that would be a major step forward.  However,  we 
estimate that the RNA extracted from paraﬃn-
embedded specimens would be shortened and show 
degradation.  We will investigate possible solutions in 
a future study.
　 In addition,  we do not know the exact prognosis of 
this rare type of AMKL due to the relative dearth of 
previous reports [8-11].  Older studies have reported 
a poor prognosis [9,  10],  but more recent reports 
have described a relatively good prognosis compared 
to other types of AMKL [1,  2,  11].  In the AML99 
study,  2 of 3 previous cases also survived more than 
5 years with complete remission.  A further large 
study including accurate diagnosis of this type of 
AMKL using the RBM15-MKL1 fusion transcript will 
be needed.
　 In addition,  it remains unknown what other 
molecular events may be associated with the RBM15-
MKL1 fusion transcript in AMKL with t(1 ; 22)
(p13 ; q13).  Hama et al.  reported that there was no 
mutation in several established AML-related genes,  
such as GATA1, JAK3, JAK2, TP53, NRAS, ASXL1, 
FLT3, IDH1/2, DNMT3A, RUNX1 and CBL,  in 3 cases 
of AMKL with t(1 ; 22)(p13 ; q13) [8].  They also 
reported that there was no mutation in other types of 
nonDS-AMKL,  except for one GATA1 mutation,  and 
thus it remains uncertain what other  molecular events 
may take place  in these AMKL patients.
　 In general,  hematological CR means that the bone 
marrow blast percentage is ＜5ｵ.  On the other hand,  
molecular CR means that a single blast having a spe-
ciﬁc fusion transcript is present in less than one of 105 
or 106 normal cells.  Therefore,  patients sometimes 
show hematological CR but can not achieve molecular 
CR after induction chemotherapy.  Naturally,  molecu-
lar CR is a better response to chemotherapy than a 
hematological response.  Recently,  MRD detection has 
become very important in AML therapy,  including 
hematopoietic stem cell transplantation (HSCT).  To 
detect an early relapse after HSCT,  MRD monitoring 
is needed.  However about 40ｵ of AML patients do 
not have a speciﬁc MRD fusion transcript,  such as 
RBM15-MKL1, RUNX1-RUNXT1 (AML1-MTG8),  CBF
β-MYH11, etc.  The Wilmsʼ tumor 1 (WT1) is overex-
pressed in ＞70-80ｵ of patients with AML and thus 
can be useful for minimal residual disease (MRD) 
monitoring [12].  In the recent AML99 study,  the 
residual level of MRD after the ﬁrst induction chemo-
therapy was correlated with the prognosis of AML 
patients [12].  In this case,  the molecular remission 
seems to be quite deep,  because the nested RT-PCR 
could not detect RBM15-MKL1 fusion after the ﬁrst 
induction chemotherapy.  We therefore recommend 
that screening for this fusion transcript be conducted 
for all infants and young children with AMKL upon 
ﬁrst diagnosis.  In addition,  a future study in which 
MRD is monitored in bone marrow and peripheral 
blood to compare the clinical outcomes is warranted.  
We conclude that detection of the RBM15-MKL1 fusion 
transcript is eﬀective for the accurate diagnosis of 
AMKL as well as a useful marker for MRD.
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